New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2014
04:55 EDTOMED, OMED, OMED, MACK, MACK, MACK, KPTI, KPTI, KPTIAmerican Gastroenterological Association to hold a symposium
2014 Gastrointestinal Cancers Symposium is being held in San Francisco on January 16-18.
News For OMED;MACK;KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
10:59 EDTOMEDOncoMed management to meet with Piper Jaffray
Meetings to be held in San Francisco October 7-8 hosted by Piper Jaffray.
September 30, 2014
12:12 EDTOMEDOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
08:37 EDTOMEDOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
08:09 EDTMACKMerrimack presents additional Phase 2 biomarker data for MM-121
Subscribe for More Information
September 29, 2014
08:08 EDTKPTIKaryopharm announces clinical data for Selinexor
Subscribe for More Information
07:17 EDTOMEDOncoMed data supports phase 2 ALPINE study of tarextumab
Subscribe for More Information
September 28, 2014
14:23 EDTOMEDOncoMed demcizumab trials show 'encouraging' safety and anti-tumor activity
OncoMed Pharmaceuticals presented safety and efficacy data from two Phase 1b clinical trials of demcizumab in pancreatic cancer and non-small cell lung cancer, NSCLC, at the European Society for Medical Oncology 2014 Congress in Madrid, Spain. Results from the Phase 1b studies demonstrate that demcizumab, in combination with standard-of-care chemotherapy, is well tolerated, especially in patients where the company's risk mitigation, monitoring and truncated dosing strategies have been employed. Encouraging tumor response rates were presented at ESMO from a study of demcizumab with gemcitabine or gemcitabine plus Abraxane in patients with first-line pancreatic cancer, and from the study of demcizumab plus pemetrexed and carboplatin for the first-line treatment of Stage III/IV NSCLC. OncoMed's Phase 1b studies identified the demcizumab dosing schedules for the company's planned randomized Phase 2 proof-of-concept trials.
September 26, 2014
10:10 EDTMACKMerrimack management to meet with Brean Capital
Subscribe for More Information
09:23 EDTKPTIKaryopharm to host conference call
Subscribe for More Information
05:40 EDTMACKPharmaEngine, Merrimack Pharmaceuticals amend MM-398 license agreement
Subscribe for More Information
September 24, 2014
09:05 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
07:39 EDTMACKMerrimack to hold a conference call
Conference call to discuss the exclusive license and collaboration agreement with Baxter International for the development and commercialization of MM-398 also known as "nal-IRI" will be held on September 24 at 8:30 am. Webcast Link
07:06 EDTMACKBaxter, Merrimack enter exclusive ex-U.S. licensing deal for MM-398
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use